Cytokines as adjuvants for vaccines: antigen-specific responses differ from polyclonal responses
- PMID: 7543878
- PMCID: PMC173446
- DOI: 10.1128/iai.63.9.3241-3244.1995
Cytokines as adjuvants for vaccines: antigen-specific responses differ from polyclonal responses
Abstract
The use of cytokines in the administration of vaccines has a unique value in obtaining the appropriate immune response and in ensuring a protective outcome. Earlier studies indicating that cytokines can influence the generation of a particular antibody isotype may represent an oversimplification of a more complex problem. Several studies discussed in this review show that the effect of a given cytokine on the immune response depends on whether one examines the antigen-specific response or the polyclonal response (i.e., total serum immunoglobulins). Further, a balanced regulation of immune responsiveness is important in maintaining homeostasis of the immune system. Consequently, for any vaccine that uses cytokines to boost the response, due consideration must be given to these important variables.
Similar articles
-
Cytokine-containing liposomes as vaccine adjuvants.Eur Cytokine Netw. 1996 Dec;7(4):693-8. Eur Cytokine Netw. 1996. PMID: 9010671 Review.
-
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.Blood. 1996 Jul 1;88(1):202-10. Blood. 1996. PMID: 8704175
-
Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases.Clin Infect Dis. 1995 Dec;21(6):1439-49. doi: 10.1093/clinids/21.6.1439. Clin Infect Dis. 1995. PMID: 8749629 Review.
-
Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14. Vaccine. 2008. PMID: 18272264 Clinical Trial.
-
Modulation of immune responses with transcutaneously deliverable adjuvants.Vaccine. 2004 Jun 23;22(19):2385-90. doi: 10.1016/j.vaccine.2003.11.063. Vaccine. 2004. PMID: 15193399 Review.
Cited by
-
Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model.Med Oncol. 1999 Dec;16(4):267-78. doi: 10.1007/BF02785873. Med Oncol. 1999. PMID: 10618690
-
Immune responses to Plasmodium falciparum-merozoite surface protein 1 (MSP1) antigen, II. Induction of parasite-specific immunoglobulin G in unsensitized human B cells after in vitro T-cell priming with MSP119.Immunology. 1999 Jul;97(3):497-505. doi: 10.1046/j.1365-2567.1999.00804.x. Immunology. 1999. PMID: 10447773 Free PMC article.
-
Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants.Front Microbiol. 2018 Apr 26;9:783. doi: 10.3389/fmicb.2018.00783. eCollection 2018. Front Microbiol. 2018. PMID: 29755431 Free PMC article. Review.
-
Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund's adjuvant, and monophosphoryl lipid A.PLoS One. 2012;7(7):e40745. doi: 10.1371/journal.pone.0040745. Epub 2012 Jul 19. PLoS One. 2012. PMID: 22829882 Free PMC article.
-
Vaccination strategies for mucosal immune responses.Clin Microbiol Rev. 2001 Apr;14(2):430-45. doi: 10.1128/CMR.14.2.430-445.2001. Clin Microbiol Rev. 2001. PMID: 11292646 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical